JP2023549316A5 - - Google Patents

Info

Publication number
JP2023549316A5
JP2023549316A5 JP2023524957A JP2023524957A JP2023549316A5 JP 2023549316 A5 JP2023549316 A5 JP 2023549316A5 JP 2023524957 A JP2023524957 A JP 2023524957A JP 2023524957 A JP2023524957 A JP 2023524957A JP 2023549316 A5 JP2023549316 A5 JP 2023549316A5
Authority
JP
Japan
Application number
JP2023524957A
Other languages
Japanese (ja)
Other versions
JP2023549316A (ja
JPWO2022101458A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081610 external-priority patent/WO2022101458A1/en
Publication of JP2023549316A publication Critical patent/JP2023549316A/ja
Publication of JP2023549316A5 publication Critical patent/JP2023549316A5/ja
Publication of JPWO2022101458A5 publication Critical patent/JPWO2022101458A5/ja
Pending legal-status Critical Current

Links

JP2023524957A 2020-11-16 2021-11-15 Fapを標的としたcd40アゴニストとの併用療法 Pending JP2023549316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207768 2020-11-16
EP20207768.1 2020-11-16
PCT/EP2021/081610 WO2022101458A1 (en) 2020-11-16 2021-11-15 Combination therapy with fap-targeted cd40 agonists

Publications (3)

Publication Number Publication Date
JP2023549316A JP2023549316A (ja) 2023-11-24
JP2023549316A5 true JP2023549316A5 (https=) 2024-11-20
JPWO2022101458A5 JPWO2022101458A5 (https=) 2024-11-20

Family

ID=73452052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524957A Pending JP2023549316A (ja) 2020-11-16 2021-11-15 Fapを標的としたcd40アゴニストとの併用療法

Country Status (5)

Country Link
US (1) US20230340154A1 (https=)
EP (1) EP4244254A1 (https=)
JP (1) JP2023549316A (https=)
CN (1) CN117916261A (https=)
WO (1) WO2022101458A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
KR20250153216A (ko) * 2023-02-24 2025-10-24 상하이 맙젠 바이오텍 리미티드 Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta
WO2025255349A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2026052650A1 (en) * 2024-09-05 2026-03-12 F. Hoffmann-La Roche Ag Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-p-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
HUE036077T2 (hu) * 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
AU2018247796A1 (en) * 2017-04-04 2019-08-29 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
NZ773887A (en) * 2018-10-01 2024-11-29 Hoffmann La Roche Bispecific antigen binding molecules comprising anti-fap clone 212
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40

Similar Documents

Publication Publication Date Title
CN305679799S (https=)
CN305708891S (https=)
CN305537668S (https=)
CN305539849S (https=)
CN305542019S (https=)
CN305543886S (https=)
CN305545381S (https=)
CN305546169S (https=)
CN305547037S (https=)
CN305548566S (https=)
CN305527691S (https=)
CN305551469S (https=)
CN305552245S (https=)
CN305552607S (https=)
CN305554243S (https=)
CN305558571S (https=)
CN305559633S (https=)
CN305560870S (https=)
CN305563400S (https=)
CN305563431S (https=)
CN305569175S (https=)
CN305585781S (https=)
CN305600624S (https=)
CN305601476S (https=)
CN305604012S (https=)